Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin vs FDA-approved Antiplatelet Drugs in Healthy Subjects
NCT06933056Phase 1Completed
- Sponsor
- University of Michigan
- Start
- Sep 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of sotagliflozin in thrombosis, sponsored by University of Michigan. Primary endpoint: Platelet aggregation. Started Sep 2025; status: completed.
02
Drugs
sotagliflozin
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT06933056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933056.